PUMA BIOTECHNOLOGY, INC. Cost of Revenue
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Cost of Revenue of $12.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $12.47M, a 1.41% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $10.42M, a 1.25% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $23.13M, a 66.13% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $12.17M, a 58.16% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for fiscal 2025 was $58.16M, a 9.70% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for fiscal 2024 was $64.40M, a 2.75% increase from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for fiscal 2023 was $62.68M, a 13.77% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. cost of goods and services sold for fiscal 2022 was $55.09M, a 13.51% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.47M 10-Q · filed 2026-08-06 | $22.90M 10-Q · filed 2026-08-06 | $46.03M derived: sum of 3 quarters · filed 2026-08-06 | $58.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $10.42M 10-Q · filed 2026-05-07 | $33.55M derived: sum of 2 quarters · filed 2026-05-07 | $45.72M derived: sum of 3 quarters · filed 2026-05-07 | $58.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $35.30M derived: sum of 2 quarters · filed 2026-02-26 | $47.60M derived: sum of 3 quarters · filed 2026-08-06 | $58.16M 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.17M 10-Q · filed 2025-11-06 | $24.47M derived: sum of 2 quarters · filed 2026-08-06 | $35.03M 10-Q · filed 2025-11-06 | $48.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $12.30M 10-Q · filed 2026-08-06 | $22.86M 10-Q · filed 2026-08-06 | $36.78M derived: sum of 3 quarters · filed 2026-08-06 | $65.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.56M 10-Q · filed 2026-05-07 | $24.48M derived: sum of 2 quarters · filed 2026-05-07 | $53.57M derived: sum of 3 quarters · filed 2026-05-07 | $64.23M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $43.02M derived: sum of 2 quarters · filed 2026-02-26 | $53.68M derived: sum of 3 quarters · filed 2026-02-26 | $64.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $29.10M 10-Q · filed 2025-11-06 | $39.76M derived: sum of 2 quarters · filed 2025-11-06 | $50.48M 10-Q · filed 2025-11-06 | $74.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $10.66M 10-Q · filed 2025-08-07 | $21.39M 10-Q · filed 2025-08-07 | $45.71M derived: sum of 3 quarters · filed 2026-02-26 | $58.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $10.73M 10-Q · filed 2025-05-08 | $35.05M derived: sum of 2 quarters · filed 2026-02-26 | $48.34M derived: sum of 3 quarters · filed 2026-02-26 | $60.19M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $24.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.61M derived: sum of 2 quarters · filed 2026-02-26 | $49.46M derived: sum of 3 quarters · filed 2026-02-26 | $62.68M 10-K · filed 2026-02-26 |
| 2023-09-30 | $13.28M 10-Q · filed 2024-11-07 | $25.14M derived: sum of 2 quarters · filed 2024-11-07 | $38.36M 10-Q · filed 2024-11-07 | $55.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $11.86M 10-Q · filed 2024-08-01 | $25.07M 10-Q · filed 2024-08-01 | $41.91M derived: sum of 3 quarters · filed 2025-02-27 | $54.41M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $13.22M 10-Q · filed 2024-05-02 | $30.05M derived: sum of 2 quarters · filed 2025-02-27 | $42.55M derived: sum of 3 quarters · filed 2025-02-27 | $57.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $16.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $29.33M derived: sum of 2 quarters · filed 2025-02-27 | $44.25M derived: sum of 3 quarters · filed 2025-02-27 | $55.09M 10-K · filed 2025-02-27 |
| 2022-09-30 | $12.49M 10-Q · filed 2023-11-02 | $27.41M derived: sum of 2 quarters · filed 2023-11-02 | $38.26M 10-Q · filed 2023-11-02 | $50.15M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $14.92M 10-Q · filed 2023-08-03 | $25.76M 10-Q · filed 2023-08-03 | $37.66M derived: sum of 3 quarters · filed 2024-02-29 | $47.94M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $10.84M 10-Q · filed 2023-05-04 | $22.74M derived: sum of 2 quarters · filed 2024-02-29 | $33.02M derived: sum of 3 quarters · filed 2024-02-29 | $44.99M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $11.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $22.17M derived: sum of 2 quarters · filed 2024-02-29 | $34.14M derived: sum of 3 quarters · filed 2024-02-29 | $63.70M 10-K · filed 2024-02-29 |
| 2021-09-30 | $10.28M 10-Q · filed 2022-11-03 | $22.25M derived: sum of 2 quarters · filed 2022-11-03 | $51.81M 10-Q · filed 2022-11-03 | $62.74M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $11.97M 10-Q · filed 2022-08-04 | $41.53M 10-Q · filed 2022-08-04 | $52.47M derived: sum of 3 quarters · filed 2023-03-02 | $62.41M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $29.56M 10-Q · filed 2022-05-05 | $40.50M derived: sum of 2 quarters · filed 2023-03-02 | $50.44M derived: sum of 3 quarters · filed 2023-03-02 | |
| 2020-12-31 | $10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $20.88M derived: sum of 2 quarters · filed 2023-03-02 | $39.37M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $9.94M 10-Q · filed 2021-11-04 | $28.43M 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $36.81M 10-K · filed 2022-03-03 | |||
| 2019-06-30 | $9.32M 10-Q · filed 2019-08-09 | $17.30M 10-Q · filed 2019-08-09 | $27.66M derived: sum of 3 quarters · filed 2019-08-09 | $36.71M derived: sum of 4 quarters · filed 2019-08-09 |
| 2019-03-31 | $7.99M 10-Q · filed 2019-05-10 | $18.34M derived: sum of 2 quarters · filed 2019-05-10 | $27.39M derived: sum of 3 quarters · filed 2019-05-10 | $36.22M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-12-31 | $10.36M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $19.41M derived: sum of 2 quarters · filed 2019-03-01 | $28.24M derived: sum of 3 quarters · filed 2019-08-09 | $34.62M 10-K · filed 2019-03-01 |
| 2018-09-30 | $9.05M 10-Q · filed 2018-11-05 | $17.88M derived: sum of 2 quarters · filed 2019-08-09 | $24.26M 10-Q · filed 2018-11-05 | $28.31M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-06-30 | $8.83M 10-Q · filed 2019-08-09 | $15.21M 10-Q · filed 2019-08-09 | $19.26M derived: sum of 3 quarters · filed 2019-08-09 | $20.79M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $6.38M 10-Q · filed 2019-05-10 | $10.43M derived: sum of 2 quarters · filed 2019-05-10 | $11.96M derived: sum of 3 quarters · filed 2019-05-10 | |
| 2017-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $5.57M derived: sum of 2 quarters · filed 2019-03-01 | $5.57M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $1.53M 10-Q · filed 2018-11-05 | $1.53M 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |